Sirtex supported an extensive clinical study programme of randomised controlled studies in metastatic colorectal cancer and hepatocellular carcinoma. They were the largest studies of their kind in the world and were designed to define the optimal role for SIR-Spheres® Y-90 resin microspheres in the treatment of various inoperable primary and secondary liver tumours; and to further investigate the safety and effectiveness of SIR-Spheres Y-90 resin microspheres.
SIR-Spheres Y-90 resin microspheres are approved and indicated in over 40 countries for the treatment of patients with inoperable liver tumours.
In addition to its use in metastatic colorectal cancer and hepatocellular carcinoma, a broad range of clinical experience has been gained from patients with liver metastases from neuroendocrine tumours, breast cancer, ocular melanoma and pancreatic cancer, as well as in cholangiocarcinoma.
Sirtex is also broadening its focus to examine the use of SIR-Spheres Y-90 resin microspheres in a number of cancers outside the liver.
Please ask your doctor for more information on how you might benefit from this treatment.